1. Home
  2. ICUI vs NUVB Comparison

ICUI vs NUVB Comparison

Compare ICUI & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ICU Medical Inc.

ICUI

ICU Medical Inc.

HOLD

Current Price

$153.50

Market Cap

3.6B

Sector

Health Care

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$5.98

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICUI
NUVB
Founded
1984
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
2.9B
IPO Year
1992
N/A

Fundamental Metrics

Financial Performance
Metric
ICUI
NUVB
Price
$153.50
$5.98
Analyst Decision
Buy
Strong Buy
Analyst Count
5
9
Target Price
$179.50
$10.44
AVG Volume (30 Days)
217.4K
6.3M
Earning Date
02-26-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,320,363,000.00
$26,748,000.00
Revenue This Year
N/A
$616.63
Revenue Next Year
N/A
$202.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1137.19
52 Week Low
$107.00
$1.54
52 Week High
$175.51
$9.75

Technical Indicators

Market Signals
Indicator
ICUI
NUVB
Relative Strength Index (RSI) 58.58 29.46
Support Level $146.33 $6.07
Resistance Level $157.91 $6.63
Average True Range (ATR) 5.21 0.53
MACD 0.41 -0.39
Stochastic Oscillator 76.51 11.03

Price Performance

Historical Comparison
ICUI
NUVB

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Share on Social Networks: